Physician profile
Grant E Nitzel
NPI 1104821149
$2,878.15
in general payments reported to CMS, 2019-2025
30 companies · $256 in 2025
The $256 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $312 · 2021: $434 · 2022: $501 · 2023: $660 · 2024: $410 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,326.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,274.75 | 2020-2025 | |
| Amgen INC. | $197.49 | 2019-2024 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $170.15 | 2019-2021 | |
| Lilly USA, LLC | $118.44 | 2019-2024 | Mounjaro, Jardiance |
| Otsuka America Pharmaceutical, INC. | $113.40 | 2023-2025 | Rexulti |
| Allergan, INC. | $108.03 | 2019-2021 | |
| Novo Nordisk INC | $96.59 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Biohaven Pharmaceutical Holding Company Ltd. | $94.25 | 2022 | |
| Pfizer INC. | $77.68 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $69.84 | 2020-2024 | Invega Sustenna |
| Sanofi-Aventis U.S. LLC | $48.57 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.56 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $44.69 | 2019-2025 | Austedo Xr, Austedo |
| Bayer Healthcare Pharmaceuticals INC. | $42.77 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.67 | 2025 | Caplyta |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $41.66 | 2020 | |
| Gilead Sciences, INC. | $37.69 | 2020-2025 | Epclusa |
| Abiomed | $34.71 | 2025 | |
| Exact Sciences Corporation | $32.59 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $27.19 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $26.04 | 2020-2023 | Livalo, Seglentis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.18 | 2025 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $17.31 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.84 | 2019 | |
| Astellas Pharma US INC | $14.94 | 2023 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $13.85 | 2023 | Trintellix |
| Lexicon Pharmaceuticals, INC. | $13.69 | 2023 | Inpefa |
| Organon LLC | $13.48 | 2023 | Nexplanon |
| Alkermes, INC. | $12.69 | 2022 | |
| Dexcom, INC. | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grant Nitzel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.